Abivax Shares Rise Against the CAC 40 Trend, Up 1923% Over the Year
The French biotech company's stock increased by 2.77% this Thursday to €103.80, in a declining Paris market. This rise occurs as the CAC 40 drops by 0.72% during the session, to 8,204.70 points, while Abivax's annual performance exceeds 1900%.
In mid-morning trading, Abivax was exchanged at €103.80, up by 2.77% from yesterday's close of €101. This rebound brings the weekly gain to 1.77% and the three-month gain to 4.64%. Over one year, the trajectory remains exceptional with a leap of 1923%. Technically, the price is moving above its three moving averages: MM20 at €100.23, MM50 at €100.89, and MM200 at €80.80. This alignment indicates a strong upward trend. The RSI, at 51, remains in the neutral zone, currently showing no signs of overbuying. The stock is positioned in the upper part of its Bollinger Bands (65%), with the upper bound at €112.25 and the lower bound at €88.22, yet it has not reached the threshold that would indicate excessive tension. The nearest resistance is at €109.60, a level that could be the next test for the stock.
Upcoming Financial Milestones
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Abivax's next financial appointment is scheduled for June 1, 2026, when it will publish its first-quarter results. This will be followed by the half-yearly accounts on September 14, and the third-quarter results on December 14. These dates will provide market participants with visibility on the progress of clinical programs and the company's cash consumption. On this Thursday, the pharmaceutical and biotech sector shows mixed performance on the Parisian market: Sanofi is up by 0.36% while UCB is down by 0.97%. Abivax's monthly volatility remains particularly high at 56.27, consistent with the risk profile of a biotech company in the development phase. The negative beta of -3.41 also illustrates a significant decorrelation with the overall market, giving the stock a unique behavior in response to fluctuations in major indices.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
